{"entity":{"id":"radioembolisation-tare","kind":"technology","name":"Radioembolisation (TARE / SIRT, yttrium-90)","aka":[],"tldr":"Millions of tiny radioactive glass or resin beads are injected into the liver artery, lodging in the tumour and irradiating it from within.","summary":"Yttrium-90 microspheres (TheraSphere glass, SIR-Spheres resin) deliver beta radiation to hepatic tumours. Randomised trials versus sorafenib in advanced HCC (SARAH, SIRveNIB) were negative for OS but showed better tolerability and response; personalised dosimetry (DOSISPHERE-01) and radiation segmentectomy (LEGACY) established curative-intent use in early-stage disease. Standard alternative to TACE and a bridge or downstaging tool to transplant.","status":"established","asOf":"2026-09-07","wikipedia":"https://en.wikipedia.org/wiki/Selective_internal_radiation_therapy","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Selective_internal_radiation_therapy"}],"tags":[],"related":["y-90"],"indications":["hcc","neuroendocrine"],"sections":[],"technologies":["radioligand-therapy","spect"],"targets":[],"drugs":[],"companies":["sirtex","boston-scientific"],"institutions":[],"pathways":[],"terms":["dosimetry"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"principle":"Arterial delivery of 20-60 µm microspheres carrying 90Y (beta emitter, 2.5 mm mean path, 64 h half-life); dose planned from 99mTc-MAA mapping and lung shunt fraction.","strengths":["Outpatient, single session","Effective in portal vein thrombosis where TACE is contraindicated","Radiation segmentectomy can be curative for small tumours"],"limitations":["Radioembolisation-induced liver disease","Failed to beat sorafenib on OS in advanced disease","Lung shunting excludes some patients"],"since":2002},"route":"/technologies/radioembolisation-tare/","neighbours":{"isotope":[{"id":"ho-166","kind":"isotope","name":"Holmium-166","route":"/isotopes/ho-166/"},{"id":"y-90","kind":"isotope","name":"Yttrium-90","route":"/isotopes/y-90/"}],"indication":[{"id":"hcc","kind":"indication","name":"Hepatocellular carcinoma","route":"/indications/hcc/"},{"id":"hcc-intermediate","kind":"indication","name":"Intermediate hepatocellular carcinoma (BCLC B)","route":"/indications/hcc-intermediate/"},{"id":"neuroendocrine","kind":"indication","name":"Neuroendocrine tumours","route":"/indications/neuroendocrine/"},{"id":"pancreatic-net","kind":"indication","name":"Pancreatic neuroendocrine tumours","route":"/indications/pancreatic-net/"},{"id":"small-intestinal-net","kind":"indication","name":"Small intestinal neuroendocrine tumours","route":"/indications/small-intestinal-net/"}],"technology":[{"id":"radioligand-therapy","kind":"technology","name":"Radioligand therapy (beta emitters)","route":"/technologies/radioligand-therapy/"},{"id":"spect","kind":"technology","name":"SPECT & bone scan","route":"/technologies/spect/"}],"company":[{"id":"boston-scientific","kind":"company","name":"Boston Scientific","route":"/companies/boston-scientific/"},{"id":"bwxt-medical","kind":"company","name":"BWXT Medical","route":"/companies/bwxt-medical/"},{"id":"quirem-medical","kind":"company","name":"Quirem Medical","route":"/companies/quirem-medical/"},{"id":"sirtex","kind":"company","name":"Sirtex Medical","route":"/companies/sirtex/"}],"term":[{"id":"dosimetry","kind":"term","name":"Dosimetry","route":"/terms/dosimetry/"}],"trial":[{"id":"sarah-sirvenib","kind":"trial","name":"SARAH and SIRveNIB","route":"/trials/sarah-sirvenib/"}],"drug":[{"id":"ho-166-microspheres","kind":"drug","name":"Holmium-166 microspheres","route":"/drugs/ho-166-microspheres/"},{"id":"tc-99m-maa","kind":"drug","name":"Technetium Tc-99m albumin aggregated (MAA)","route":"/drugs/tc-99m-maa/"},{"id":"y-90-glass-microspheres","kind":"drug","name":"Yttrium-90 glass microspheres","route":"/drugs/y-90-glass-microspheres/"},{"id":"y-90-resin-microspheres","kind":"drug","name":"Yttrium-90 resin microspheres","route":"/drugs/y-90-resin-microspheres/"}],"section":[{"id":"f-radioembolisation","kind":"section","name":"Radioembolisation","route":"/fronts/f-radioembolisation/"}],"pairing":[{"id":"tare-vs-sorafenib-caution","kind":"pairing","name":"Radioembolisation (TARE) compared with sorafenib in hepatocellular carcinoma","route":"/pairings/tare-vs-sorafenib-caution/"},{"id":"tare-plus-durvalumab-hcc","kind":"pairing","name":"Radioembolisation (TARE) with durvalumab in hepatocellular carcinoma","route":"/pairings/tare-plus-durvalumab-hcc/"}],"person":[{"id":"erik-mittra","kind":"person","name":"Erik S. Mittra","route":"/people/erik-mittra/"}]}}